FibroGen Inc (FGEN) Receives Analyst Rating

FibroGen Inc (FGEN) : Zacks Investment Research ranks FibroGen Inc (FGEN) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 3 research analysts is 1, which indicates as a Strong Buy.

FibroGen Inc (FGEN) : The most positive equity analysts on FibroGen Inc (FGEN) expects the shares to touch $52, whereas, the least positive believes that the stock will trade at $33 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $42.5 with an expected fluctuation of $13.44 from the mean.


FibroGen Inc (NASDAQ:FGEN): After opening at $19.12, the stock dipped to an intraday low of $18.95 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $20.58 and the buying power remained strong till the end. The stock closed at $20 for the day, a gain of 4.60% for the day session. The total traded volume was 615,391. The stocks close on the previous trading day was $19.12.

FibroGen, Inc. is a research-based, biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic agents. Its lead product candidate is roxadustat, or FG-4592 is an oral small molecule inhibitor of hypoxia inducible factor-prolyl hydroxylase (HIF-PHs), in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). The Companys second product candidate, FG-3019, is a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis. Roxadustat is a HIF-PH inhibitor that acts by stimulating the bodys natural pathway of erythropoiesis, or red blood cell production. FG-5200 is a corneal implant. Its product FG-3019 blocks FG-3019 blocks CTGF (CTGF). FG-6874 is a HIF-PH inhibitor. FG-8205 is in preclinical evaluation for use as a cardioprotective agent to prevent the onset of heart failure following a heart attack.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *